我国基本药物遴选和省级增补情况分析  

Analysis of the Selection of National Essential Drug List and the Additional Essential Drug List

作　　者：娄兰翔 周引德 何常楠 傅鸿鹏[1,2] 

机构地区：[1]卫生部卫生发展研究中心,北京100191 [2]首都医科大学

出　　处：《中国药事》2014年第11期1178-1181,共4页Chinese Pharmaceutical Affairs

基　　金：中英繁荣基金(编号14SS2)

摘　　要：目的分析我国现行基本药物目录遴选情况,发现问题并探讨改进方法,为下一步基本药物遴选工作提供建议。方法分析整理国家目录和省级增补目录制定中的相关文件,针对研究主题开展专家访谈,对部分省份进行重点调研,归纳国家和省级基本药物目录增补数量和增补流程,讨论其中存在的问题和对策。结果国家目录制定和各省增补程序大致相同,但在遴选范围、推荐机构及其他相关细节上有所不同,有些省份增补药品次数频繁。总体上看,无论国家还是省级,在增补过程中均缺乏科学的遴选依据,过于依赖主观意见,增补方法和流程有待完善。结论当前,基本药物目录进入微调阶段,应考虑引入药物经济学及循证医学评价,增加评价参与者,将整个遴选流程规范化、透明化。Objective To analyze the selection of National Essential Drug List（EDL）and Provincial Additional List,find the problems and discuss the updated methods in order to offer advices for the further selection of Essential Drug List. Methods Collecting and analyzing the relevant documents,carrying out expert interviews and conducting the survey in some provinces to summarize the number and process of EDL selection at national and provincial level.The existing problems and solution were discussed.Results The processes of National EDL selection and Provincial EDL supplement were similar,with some differences in such details as the selection scope and referrers,and some provinces supplemented the Provincial Additional List much too frequently.In general,at both national and provincial levels,there were very few scientific grounds in the selection process,and the method and process should be updated and optimized.Conclusion Currently,the EDL entered the stage of fine-tuning,during which pharmaco-economics and evidence-based evaluation should be applied. More participants should be engaged in the discussion and evaluation in order to make the selection process more standardized and transparent.

关 键 词：基本药物 遴选程序 药物经济学 

分 类 号：R95[医药卫生—药学]